Innovations in the News

Texas A&M Innovation and Technologies Help Develop Solutions to Address the Coronavirus (COVID-19) Pandemic


As the novel Coronavirus becomes a growing threat with significant consequences impacting all corners of the globe, Texas A&M faculty and their innovations are being utilized by local industry partners to make breakthroughs in the fight against the COVID-19 pandemic.

As the race for the cure continues, Texas A&M University technologies, faculty innovators, and industry partners are working around the clock to devise solutions to combat the novel coronavirus and end the current pandemic.  The new innovations already surfacing hold promising outlooks for the future and have given us hope that there will soon be a cure.
 

Pulmotect-FINAL.jpg  Texas A&M, MD Anderson scientists testing inhaled
  therapuetic to protect against COVID-19

  Drug developed in Houston has been approved for two human
  clinical trials by the Food and Drug Administration
 
  By Alyssa Gafford-Gaby, Texas A&M University Innovation  
  Partners • July 8, 2020
 
  In a joint effort between biopharmaceutical company Pulmotect,
  MD Anderson Cancer Center and Texas A&M University, a drug
  that has been under development for several years could
  provide short-term immunity against COVID-19.
 
  View Full Article 

Photo Credit: Texas A&M Health Science Center
  


Drug-Discovery-Center-Lui-FINAL.jpg  Chemistry Lab at Texas A&M looking at alternatives to Remdesivir
  to treat COVID-19

  Source: Texas A&M College of Science
  Original publish date: March 26, 2020
  View Full Article

Photo Credit: Texas A&M College of Science

In the heart of Aggieland, while most people are working remotely, scientists at the Texas A&M Drug Discovery Center in College Station, TX are busy working on new therapeutics to cure COVID-19 infections. Dr. Wenshe Liu, chemistry professor and director of the center, was the first to explain scientific rationale behind Remdesivir, the only FDA approved drug for COVID-19 patients. The team is developing additional drugs through biochemical modification to attack the virus from different aspects. According to Liu, given the current size of infected population and speed of viral mutation, multi-point attacking is the only solution to prevent the rise of drug resistance. On the urgency to react, Liu says “the motivation that drove us was the rush against time to find alternative medicines that might be put in use to fight against the virus when it spread to the U.S.”  
 


Celltex-FINAL.jpg  Celltex utilizing Texas A&M stem-cell technology to combat COVID-19
  Source: Business Wire
  Original publish date: March 16, 2020
  View Full Article


Photo Credit: Business Wire
 

Celltex Therapeutics Corporation, a biotech company based out of Houston, has partnered with technology out of Texas A&M University’s Institute for Regenerative Medicine and made significant progress in understanding adult autologous Mesenchymal Stem Cells (MSCs). Based on a recent study, patients suffering from autoimmune disorders, debilitating diseases, and respiratory conditions, such as COVID-19 pneumonia, could be treated using the MSC technology as it has proven to be an effective approach against fighting the Coronavirus.  
 



iBio-Testing.jpg  iBio CDMO partners with Texas A&M to develop COVID-19 vaccine
  Source: Globe Newswire
  Original publish date: March 26, 2020
  View Full Article 


Photo Credit: KBTX

iBio, a biotechnology company based in New York with CDMO facilities located right here in Brazos County, is working to find a solution to fight COVID-19. Through a master agreement, collaboration between iBio and Texas A&M, efforts are underway to conduct further research aimed at developing a new vaccine. iBio’s program, IBIO-200, uses a Virus Like Particle (VLP) from SARS-Cov-2, and according to Dr. James Samuel, Head of the Department of Microbial Pathogenesis and Immunology at Texas A&M University, “[they] see strong potential for the IBIO-200 program given that [they] have both the glycosylated and non-glycosylated iBio VLPs as options for development,” and that “[they] look forward to completing the preclinical immunization studies for iBio to determine the optimal combination of VLP and adjuvant to advance to human clinical trials.”